This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: apheresis

October 2016

Watch our ESC podcasts

BJCardio Staff

Abstract

For advances in atrial fibrillation, we talk to Professor John Camm (St George’s, University of London), who analyses new AF guidance and the registry ‘real world’ data emerging in this field. Dr Jubin Joseph (St Thomas’ Hospital, London, and President of the British Junior Cardiologists’ Association) speaks about the implications of some of the coronary artery disease studies, and also the use of telemonitoring in heart failure. Finally, Professor Patrick Moriarty (University of Kansas Medical Center, Kansas City, USA) discusses what effect the new PCSK9 inhibitors are likely to have on life for patients with familial hypercholesto

| Full text

October 2016 Br J Cardiol 2016;23:133–5

News from the ESC Congress 2016

BJCardio Staff

Abstract

More news from ESC available online More news reports from the ESC are available online at www.bjcardio.co.uk/news including: • His Holiness Pope Francis (below) makes historic visit • REM-HF study shows no benefit with remote monitoring of cardiac devices • ODYSSEY ESCAPE: alirocumab reduces need for apheresis in FH • Apheresis shows promise in refractory angina • Pulmonary hypertension and anticoagulation highlights at congress • Our practice message podcasts (see below) ENSURE AF: edoxaban allows prompt cardioversion in AF Patients with atrial fibrillation (AF) who need anticoagulation before undergoing cardioversion may benefi

| Full text

March 2008 Br J Cardiol 2008;15:83-85

Low-density lipoprotein-apheresis: an update

Stefanos Archontakis, Alison Pottle, Mahmoud Barbir

Abstract

Indications, techniques and effects Low density lipoprotein (LDL)-apheresis is a selective lipid-lowering extracorporeal treatment where LDL and other atherogenic apoB-lipoproteins are removed from circulation while high-density lipoprotein (HDL) remains virtually unchanged. In the last years, individual authors as well as various scientific organisations have proposed different indications for using LDL-apheresis. The most widely used guidelines are those of the Food and Drug Administration (FDA) in the USA,1 of the Federal Committee of Physicians and Health Insurance Funds in Germany2 and recently, those of the International Panel on the M

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now